Artrya secures UK, EU approvals for Salix
Within a week, ASX-listed medtech company Artrya received both regulatory approvals from the European Union and the United Kingdom for its Salix Coronary Anatomy product.
The AI-powered software identifies and analyses arterial plaque to diagnose coronary artery disease.
The recent certifications allow Artrya to market Salix in 28 EU member countries and...
Australia-listed medtech firm Artrya has disclosed that its subsidiary in the United States has signed a clinical partnership with Alabama-based Huntsville Heart Center.
According to a media release, an initial agreement between the companies involves a study to determine the efficacy of Artrya's AI technology for diagnosing coronary heart disease.
WHY IT MATTERS
The Artrya Salix is an AI-powered...
Medical technology firm Artrya has been cleared by the Australian government to commercialise an AI tool that diagnoses coronary heart disease. It has partnered with Perth-based radiology practice Envision Medical Imaging to market the product by early next year.
WHAT IT'S ABOUT
The AI tool,Salix, has been developed through the collaboration of researchers from the University of Western Australia...
